Avirmax Biopharma Inc, a clinical stage biopharmaceutical company developing next-generation gene therapies for retina diseases, announced on Friday that it has started an Investigational New Drug (IND)-enabling studies of ABI-201, a breakthrough gene therapy for dry age-related macular degeneration.
ABI-201 is a potential first-in-class AAV vector that delivers three genes to correct the dysregulation of complement activation, anti-inflammation, to protect retinal pigment epithelia and photoreceptors as well as to block retinal neovascularisation.
In vivo studies conducted across multiple animal species have demonstrated the anticipated biological functions of the therapeutic genes encoded by the ABI-201 vector.
Avirmax Biopharma anticipates submitting an IND application for ABI-201 in the fourth quarter of 2025. Pending regulatory clearance, the company plans to initiate phase 1/2a trials in patients with dry AMD shortly thereafter.
Akeso completes patient enrolment for cadonilimab Phase III registrational clinical trial
Jazz Pharmaceuticals to acquire Chimerix in USD935m deal to expand oncology portfolio
Dermata Therapeutics completes treatment in XYNGARI Phase 3 acne trial
Bloom Science's BL-001 shows positive results in Phase 1 trial
Heyou Hospital, China orders treatment planning system from RaySearch
ONWARD Medical secures funding to advance Parkinson's disease research
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
Raziel and Fosun Pharma commence phase 3 RZL-012 study in China
CStone Pharmaceuticals reports first patient dosed in CS2009 Phase I trial
Celltrion's STOBOCLO and OSENVELT biosimilars receive US FDA approval
Faron Pharmaceuticals' bexmarilimab receives FDA Orphan Drug Designation for MDS
Protagonist and Takeda report positive Phase 3 results for rusfertide in polycythemia vera
GSK demonstrates significant improvement in CRSwNP treatment with depemokimab at 2025 AAAAI
Australia declines approval for BioArctic and Eisai's Alzheimer's drug lecanemab